Calibrate Reviews Metformin
Used alongside incretin therapy for members with glycemic indications rather than as a standalone weight intervention or a required first rung.
Sold as Glucophage · Reviewed September 19, 2026
What “Adjunct” means here
Available and used, but not the centre of the protocol — typically alongside or after another agent.
The pairing
How Calibrate handles Metformin
These are the vendor-specific mechanics that determine what this molecule actually costs you and whether members stay on it long enough to benefit.
- Access status
- Adjunct
- Gating
- Clinical indication, typically prediabetes or type 2 diabetes.
- Prescribes directly
- Yes
- Step therapy
- No
- Prior authorization
- Yes
- Titration protocol
- Physician-directed titration with mandatory quarterly video visits and lab monitoring
- Off-ramp
- One-year maintenance curriculum after target weight, coach-led
- Care team
- Board-certified physicians, Nurse practitioners, Accountability coaches
Ask Calibrate this
What percentage of your population is maintained on metformin alone, without ever escalating to a GLP-1?
Watch out
The weight-loss guarantee excludes pharmacy spend entirely. It protects the program fee, not your budget.
The molecule
Metformin in one page
Not a GLP-1, and not a weight-loss drug — but the first rung of nearly every credible step-therapy protocol, and effectively free. How a vendor uses metformin tells you whether its cost discipline is real.
Clinical profile
- Drug class
- Biguanide
- Brand names
- Glucophage — Type 2 diabetes
- Mechanism
- Reduces hepatic glucose production and improves insulin sensitivity. Weight effect is modest and secondary to the glycemic effect.
- Administration
- Oral, daily, usually with an extended-release formulation to improve tolerability.
- Titration
- Gradual escalation over several weeks, primarily to manage gastrointestinal tolerability.
- Typical result
- Modest weight reduction — typically low single digits as a percentage — alongside meaningful glycemic improvement in appropriate patients.
- Generic available
- Yes
Known side effects
- Gastrointestinal effects, substantially reduced by extended-release formulations
- Long-term B12 depletion warranting periodic monitoring
- Lactic acidosis, rare and largely confined to renal impairment
What benefits teams need to know
A useful test of vendor honesty
Every vendor lists metformin. Far fewer can show you what share of their population is maintained on it without escalating. Ask for that number — it separates vendors with a step-therapy protocol from vendors with a step-therapy slide.
It does not compete with GLP-1s on weight
Metformin is not an alternative to incretin therapy for a member who needs substantial reduction. Its role is identifying the members who never needed the expensive drug, not substituting for it in those who do.
Alternatives
Other vendors and Metformin
Same molecule, materially different access rules. The status column is where the cost difference lives.
| Vendor | Access | Score | PMPM |
|---|---|---|---|
| Virta Health Metabolic specialist | First-line | 8.7 | $40–$95 |
| Form Health Full-service clinical | Adjunct | 8.0 | $58–$105 |
| Twin Health Metabolic specialist | First-line | 7.8 | $55–$120 |
| Found Full-service clinical | First-line | 7.6 | $45–$85 |
| Vida Health Full-service clinical | First-line | 7.5 | $38–$78 |
| Teladoc Health Navigation & orchestration | First-line | 7.4 | $18–$44 |
Same vendor
Calibrate across the formulary
How this vendor positions each molecule tells you more about its cost discipline than any single review does.
A first-line option with no required lower-cost trial. Physician-directed titration with quarterly video visits and lab monitoring is genuinely above the market norm for clinical intensity.
Treated interchangeably with semaglutide as a first-line choice, selected on tolerability and coverage rather than on a cost hierarchy. The quarterly physician cadence carries across.
Available but rarely the starting point. In practice it appears where the weekly agents are contraindicated or unavailable rather than as a deliberate cost step.